BRISTOL-MYERS SQUIBB COMPANY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $22.32 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $22.32B.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $20.10B.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $18.51B.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $18.60B.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $22.32B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $20.10B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $18.51B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $18.60B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $17.49B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $17.45B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $16.39B 10-K · filed 2026-02-11 |
| 2024-09-30 | $17.20B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $17.07B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $16.55B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $29.48B 10-K · filed 2025-02-12 |
| 2023-09-30 | $29.06B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $32.03B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $31.89B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $31.12B 10-K · filed 2024-02-13 |
| 2022-09-30 | $32.73B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $32.66B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $31.64B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $36.01B 10-K · filed 2023-02-14 |
| 2021-09-30 | $37.28B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $36.87B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $37.67B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $37.88B 10-K · filed 2022-02-09 |
| 2020-09-30 | $50.23B 10-K · filed 2021-02-10 |
| 2020-06-30 | $49.16B 10-K · filed 2021-02-10 |
| 2020-03-31 | $49.98B 10-K · filed 2021-02-10 |
| 2019-12-31 | $51.70B 10-K · filed 2021-02-10 |
| 2019-09-30 | $17.75B 10-K · filed 2021-02-10 |
| 2019-06-30 | $16.15B 10-K · filed 2021-02-10 |
| 2019-03-31 | $15.32B 10-K · filed 2021-02-10 |
| 2018-12-31 | $14.13B 10-K · filed 2020-02-24 |
| 2018-09-30 | $13.75B 10-K · filed 2020-02-24 |
| 2018-06-30 | $12.42B 10-K · filed 2020-02-24 |
| 2018-03-31 | $12.91B 10-K · filed 2020-02-24 |
| 2017-12-31 | $11.85B 10-K · filed 2019-02-25 |
| 2017-09-30 | $14.91B 10-K · filed 2019-02-25 |
| 2017-06-30 | $14.82B 10-K · filed 2019-02-25 |
| 2017-03-31 | $14.54B 10-K · filed 2019-02-25 |
| 2016-12-31 | $16.35B 10-K · filed 2018-02-13 |
| 2016-09-30 | $15.78B 10-K · filed 2018-02-13 |
| 2016-06-30 | $15.08B 10-K · filed 2018-02-13 |
| 2016-03-31 | $14.55B 10-K · filed 2018-02-13 |
| 2015-12-31 | $14.42B 10-K · filed 2017-02-21 |
| 2015-09-30 | $15.27B 10-K · filed 2017-02-21 |
| 2015-06-30 | $15.29B 10-K · filed 2017-02-21 |
| 2015-03-31 | $15.69B 10-K · filed 2017-02-21 |
| 2014-12-31 | $14.98B 10-K · filed 2016-02-12 |
| 2014-09-30 | $15.20B 10-K · filed 2016-02-12 |
| 2014-06-30 | $15.38B 10-K · filed 2016-02-12 |
| 2014-03-31 | $15.53B 10-K · filed 2016-02-12 |
| 2013-12-31 | $15.24B 10-K · filed 2015-02-13 |
| 2013-09-30 | $14.71B 10-K · filed 2015-02-13 |
| 2013-06-30 | $14.37B 10-K · filed 2015-02-13 |
| 2013-03-31 | $13.70B 10-K · filed 2015-02-13 |
| 2012-12-31 | $13.64B 10-K · filed 2014-02-14 |
| 2012-09-30 | $13.90B 10-K · filed 2014-02-14 |
| 2012-06-30 | $15.81B 10-K · filed 2014-02-14 |
| 2012-03-31 | $16.25B 10-K · filed 2014-02-14 |
| 2011-12-31 | $15.87B 10-K · filed 2013-02-15 |
| 2011-09-30 | $16.44B 10-K · filed 2013-02-15 |
| 2011-06-30 | $16.14B 10-K · filed 2013-02-15 |
| 2011-03-31 | $15.90B 10-K · filed 2013-02-15 |
| 2010-12-31 | $15.64B 10-K · filed 2012-02-17 |
| 2010-09-30 | $15.86B 10-Q · filed 2010-10-26 |
| 2010-06-30 | $15.57B 10-Q · filed 2010-07-22 |
| 2010-03-31 | $15.23B 10-Q · filed 2010-04-29 |
| 2009-12-31 | $14.79B 10-K · filed 2011-02-18 |
| 2009-09-30 | $14.37B 10-Q · filed 2009-10-22 |
| 2008-12-31 | $12.21B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |